new glp 1 receptor agonists GLP-1 as Treatments for Type 2 Diabetes GLP-1 receptor agonists | How

Explore the implications of proposed changes to GLP-1 medication coverage and their impact on Medicare and Medicaid health plans

Mattioli Introduction GLP-1 agonists like liraglutide have become a powerful tool for weight management, but they often come with digestive side effects and concerns about long-term use

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for glycaemic control and weight loss in patients with type 2 diabetes (T2D)

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results